Dental implants maker Straumann raises 2022 sales outlook

This post was originally published on this site

The company, which specialises in tooth replacement and orthodontic solutions, expects its revenue to grow in the mid-teens percentage range organically, against its earlier forecast for low-double-digit percentage growth.

Straumann’s third-quarter organic sales came in at 551 million Swiss francs ($552 million), up 12% compared to last year.

“We were able to deliver a very good quarter despite the ongoing macro-economic uncertainties,” Chief Executive Guillaume Daniellot said in a statement.

Dental care providers, who last year benefited from increased demand for specialty treatments as practices reopened after the easing of COVID-19-related lockdowns, have now also been reassured by fewer lockdowns in core market China.

The country represents more than half of Straumann’s overall business in the Asia-Pacific region, where sales grew by almost 9% organically in the third quarter.

Straumann confirmed its full-year guidance for core earnings before interest and taxes (EBIT) margin of around 26%, including significant growth investments.

($1 = 0.9985 Swiss francs)